The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs

Abstract

Antigen presentation, as the initial step in inducing the activation of T lymphocytes, plays a crucial role in antitumor response. Studies concentrating on major histocompatibility complex class II (MHC II) molecules and the activated CD4⁺ helper T (Th) cells have gained popularity in light of the past limited efficacy of MHC I-activated CD8⁺ T cells alone. In general, MHC II is canonically expressed by professional antigen-presenting cells (pAPCs), yet attempts to increase antigen presentation by dendritic cell (DC) activation have mostly been unsuccessful. In recent years, a number of studies have found that a variety of cells, including cancer cells, fibroblasts, vascular endothelial cells (VECs), and lymphoid stromal cells (LSCs), are considered amateur APCs (aAPCs) and can express MHC II molecules, which have piqued the interest of researchers. These groups vastly outnumber DCs or macrophages, and it has been confirmed that they also qualify as antigen-presenting complexes that are functionally related to conventional pAPCs. Herein, we will review current research regarding the antigen presentation process of MHC II, its advances in APC surfaces, especially for aAPCs, the special mechanisms of regulation of MHC II on aAPCs, and combination therapy targeting MHC II as a possible treatment strategy in cancer.

Keywords

antigen presentation / MHC II / aAPCs / CD4⁺ Th cells

References

[1] Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535.

[2] Alspach E, Lussier DM, Miceli AP, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574(7780):696-701.

[3] Rock KL, Reits E, Neefjes J. Present yourself! By MHC class I and MHC class II molecules. Trends Immunol. 2016;37(11):724-737.

[4] Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577-581.

[5] Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641-645.

[6] Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692-696.

[7] Darragh LB, Karam SD. Amateur antigen-presenting cells in the tumor microenvironment. Mol Carcinog. 2022;61(2):153-164.

[8] Harryvan TJ, de Lange S, Hawinkels LJAC, Verdegaal EME. The ABCs of antigen presentation by stromal non-professional antigen-presenting cells. Int J Mol Sci. 2021;23(1):137.

[9] Yang Y, Sun J, Wang Z, et al. Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. J Thorac Oncol. 2021;16(12):2109-2120.

[10] Terasaki PI. A brief history of HLA. Immunol Res. 2007;38(1-3):139-148.

[11] Klein J, Sato A. The HLA system. N Engl J Med. 2000;343(11):782-786.

[12] Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54(1):15-39.

[13] Santambrogio L. Molecular determinants regulating the plasticity of the MHC class II immunopeptidome. Front Immunol. 2022;13:878271.

[14] Trowsdale J. Genomic structure and function in the MHC. Trends Genet. 1993;9(4):117-122.

[15] Unanue ER, Turk V, Neefjes J. Variations in MHC class II antigen processing and presentation in health and disease. Annu Rev Immunol. 2016;34:265-297.

[16] Arnold PY, La Gruta NL, Miller T, et al. The majority of immunogenic epitopes generate CD4⁺ T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol. 2002;169(2):739-749.

[17] Southwood S, Sidney J, Kondo A, et al. Several common HLADR types share largely overlapping peptide binding repertoires. J Immunol. 1998;160(7):3363-3373.

[18] Linnemann C, van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4⁺ T cells in human melanoma. Nat Med. 2015;21(1):81-85.

[19] Accolla RS, De Lerma Barbaro A, Mazza S, Casoli C, De Maria A, Tosi G. The MHC class II transactivator: prey and hunter in infectious diseases. Trends Immunol. 2001;22(10):560-563.

[20] Accolla RS, Scarpellino L, Carra G, Guardiola J. Trans-acting element(s) operating across species barriers positively regulate expression of major histocompatibility complex class II genes. J Exp Med. 1985;162(4):1117-1133.

[21] Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J Exp Med. 1986;164(1):369-374.

[22] Guardiola J, Scarpellino L, Carra G, Accolla RS. Stable integration of mouse DNA into Ia-negative human B-lymphoma cells causes reexpression of the human Ia-positive phenotype. Proc Natl Acad Sci USA. 1986;83(19):7415-7418.

[23] Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993;75(1):135-146.

[24] Muhlethaler-Mottet A. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997;16(10):2851-2860.

[25] Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol. 2000;20(17):6185-6194.

[26] Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B. Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1. Immunity. 1998;8(2):157-166.

[27] van der Stoep N, Quinten E, van den Elsen PJ. Transcriptional regulation of the MHC class II trans-activator (CIITA) promoter III: identification of a novel regulatory region in the 5’-untranslated region and an important role for cAMP-responsive element binding protein 1 and activating transcription factor-1 in CIITA-promoter III transcriptional activation in B lymphocytes. J Immunol. 2002;169(9):5061-5071.

[28] Piskurich JF, Linhoff MW, Wang Y, Ting JP. Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β. Mol Cell Biol. 1999;19(1):431-440.

[29] Sartoris S, Valle MT, Barbaro ADL, et al. HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA: acquisition of antigen processing and presentation capacity. J Immunol. 1998;161(2):814-820.

[30] Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA. 1997;94(13):6886-6891.

[31] Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science. 1994;265(5168):106-109.

[32] Beresford GW, Boss JM. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol. 2001;2(7):652-657.

[33] Tzortzakaki E, Spilianakis C, Zika E, Kretsovali A, Papamatheakis J. Steroid receptor coactivator 1 links the steroid and interferon γ response pathways. Mol Endocrinol. 2003;17(12):2509-2518.

[34] Busch R, Cloutier I, Sékaly RP, Hämmerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J. 1996;15(2):418-428.

[35] Jiang Y, Arase N, Kohyama M, et al. Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Int Immunol. 2013;25(4):235-246.

[36] Hiltbold EM, Roche PA. Trafficking of MHC class II molecules in the late secretory pathway. Curr Opin Immunol. 2002;14(1):30-35.

[37] Bikoff EK, Huang LY, Episkopou V, van Meerwijk J, Germain RN, Robertson EJ. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4⁺ T cell selection in mice lacking invariant chain expression. J Exp Med. 1993;177(6):1699-1712.

[38] Valečka J, Almeida CR, Su B, Pierre P, Gatti E. Autophagy and MHC-restricted antigen presentation. Mol Immunol. 2018;99:163-170.

[39] Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell. 2002;109 suppl:S21-S33.

[40] Axelrod ML, Cook RS, Johnson DB, Balko JM. Biological consequences of MHC-II expression by tumor cells in cancer. Clin Cancer Res. 2019;25(8):2392-2402.

[41] Poluektov YO, Kim A, Sadegh-Nasseri S. HLA-DO and its role in MHC class II antigen presentation. Front Immunol. 2013;4:260.

[42] Roche PA, Furuta K. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015;15(4):203-216.

[43] Schmid D, Pypaert M, Münz C. Antigen-loading compartments for major histocompatibility complex class II molecules continuously receive input from autophagosomes. Immunity. 2007;26(1):79-92.

[44] Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway, Jr. CA Sequence analysis of peptides bound to MHC class II molecules. Nature. 1991;353(6345):622-627.

[45] Lundin KU, Screpanti V, Omholt H, et al. CD4⁺ T cells kill Id⁺ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo. Cancer Immunol Immunother. 2004;53(12):1135-1145.

[46] Xie Y, Akpinarli A, Maris C, et al. Naive tumor-specific CD4⁺ T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010;207(3):651-667.

[47] Lundin KU, Hofgaard PO, Omholt H, Munthe LA, Corthay A, Bogen B. Therapeutic effect of idiotype-specific CD4⁺ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood. 2003;102(2):605-612.

[48] Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4⁺ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637-650.

[49] Accolla RS, Lombardo L, Abdallah R, Raval G, Forlani G, Tosi G. Boosting the MHC class II-restricted tumor antigen presentation to CD4⁺ T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state. Front Oncol. 2014;4:32.

[50] Mortara L, Castellani P, Meazza R, et al. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res. 2006;12(11 Pt 1):3435-3443.

[51] Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006;6(3):205-217.

[52] Haabeth OAW, Fauskanger M, Manzke M, et al. CD4⁺ T-cell-mediated rejection of MHC class II-positive tumor cells is dependent on antigen secretion and indirect presentation on host APCs. Cancer Res. 2018;78(16):4573-4585.

[53] Darragh LB, Karam SD. Amateur antigen-presenting cells in the tumor microenvironment. Mol Carcinog. 2022;61(2):153-164.

[54] Johnson DB, Estrada MV, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582.

[55] Park IA, Hwang SH, Song IH, et al. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS One. 2017;12(8):e0182786.

[56] Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S. Tumor cell expression of HLA-DM associates with a TH1 profile and predicts improved survival in breast carcinoma patients. Int Immunol. 2006;18(11):1591-1602.

[57] Oldford SA, Robb JD, Watson PH, Drover S. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. Int J Cancer. 2004;112(3):399-406.

[58] da Silva GB, Silva TG, Duarte RA, et al. Expression of the classical and nonclassical HLA molecules in breast cancer. Int J Breast Cancer. 2013;2013:250435.

[59] Feinmesser M. HLA-DR and β₂ microglobulin expression in medullary and atypical medullary carcinoma of the breast: histopathologically similar but biologically distinct entities. J Clin Pathol. 2000;53(4):286-291.

[60] Michel S, Linnebacher M, Alcaniz J, et al. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer. 2010;127(4):889-898.

[61] Bustin SA, Li SR, Phillips S, Dorudi S. Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. Tumor Biol. 2001;22(5):294-298.

[62] Callahan MJ, Nagymanyoki Z, Bonome T, et al. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res. 2008;14(23):7667-7673.

[63] Turner TB, Meza-Perez S, Londoño A, et al. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Oncotarget. 2017;8(27):44159-44170.

[64] Ghasemi F, Tessier TM, Gameiro SF, Maciver AH, Cecchini MJ, Mymryk JS. High MHC-II expression in Epstein-Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentation. Sci Rep. 2020;10(1):14786.

[65] Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J Clin Oncol. 2018;36(10):942-950.

[66] Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450):eaar3342.

[67] Johnson DB, Bordeaux J, Kim JY, et al. Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti-PD-1 therapies in metastatic melanoma. Clin Cancer Res. 2018;24(21):5250-5260.

[68] Johnson AM, Bullock BL, Neuwelt AJ, et al. Cancer cell-intrinsic expression of MHC class II regulates the immune microenvironment and response to anti-PD-1 therapy in lung adenocarcinoma. J Immunol. 2020;204(8):2295-2307.

[69] Park IA, Hwang SH, Song IH, et al. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling. PLoS One. 2017;12(8):e0182786.

[70] Forero A, Li Y, Chen D, et al. Expression of the MHC class II pathway in triple-negative breast cancer tumor cells is associated with a good prognosis and infiltrating lymphocytes. Cancer Immunol Res. 2016;4(5):390-399.

[71] Chan KL, Gomez J, Cardinez C, et al. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. Cancer Cell. 2022;40(10):1190-1206.e9.

[72] Johnson AM, Bullock BL, Neuwelt AJ, et al. Cancer cell-intrinsic expression of MHC class II regulates the immune microenvironment and response to anti-PD-1 therapy in lung adenocarcinoma. J Immunol. 2020;204(8):2295-2307.

[73] Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science. 1994;265(5168):106-109.

[74] Accolla RS, De Lerma Barbaro A, Mazza S, Casoli C, De Maria A, Tosi G. The MHC class II transactivator: prey and hunter in infectious diseases. Trends Immunol. 2001;22(10):560-563.

[75] Magner WJ, Kazim AL, Stewart C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000;165(12):7017-7024.

[76] Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol. 2003;33(5):1183-1192.

[77] Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4⁺ T lymphocytes for immunotherapy. Int J Cancer. 2010;127(7):1614-1624.

[78] Mortara L, Castellani P, Meazza R, et al. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res. 2006;12(11 Pt 1):3435-3443.

[79] Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4⁺ T cell priming and CD8⁺ T cell effector functions. Int Immunol. 2009;21(6):655-665.

[80] Bou Nasser Eddine F, Forlani G, Lombardo L, Tedeschi A, Tosi G, Accolla RS. CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4⁺ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells. Oncoimmunology. 2016;6(1):e1261777.

[81] Hochweller K, Striegler J, Hämmerling GJ, Garbi N. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol. 2008;38(10):2776-2783.

[82] Baleeiro RB, Bouwens CJ, Liu P, et al. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. Oncoimmunology. 2022;11(1):2080329.

[83] Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227-242.

[84] Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009;229(1):126-144.

[85] Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4⁺ T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2021;28(1-2):5-17.

[86] Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL. CD70 expression patterns in renal cell carcinoma. Hum Pathol. 2012;43(9):1394-1399.

[87] Shibahara I, Saito R, Zhang R, et al. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Mol Cancer. 2015;14:41.

[88] Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat Rev Immunol. 2014;14(11):719-730.

[89] Haabeth OAW, Tveita AA, Fauskanger M, et al. How do CD4⁺ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol. 2014;5:174.

[90] Boots AM, Wimmers-Bertens AJ, Rijnders AW. Antigen-presenting capacity of rheumatoid synovial fibroblasts. Immunology. 1994;82(2):268-274.

[91] Barnhoorn MC, Hakuno SK, Bruckner RS, Rogler G, Hawinkels LJAC, Scharl M. Stromal cells in the pathogenesis of inflammatory bowel disease. J Crohns Colitis. 2020;14(7):995-1009.

[92] Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102-1123.

[93] Friedman G, Levi-Galibov O, David E, et al. Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4⁺ and PDPN⁺ CAFs to clinical outcome. Nat Cancer. 2020;1(7):692-708.

[94] Harryvan TJ, Verdegaal EME, Hardwick JCH, Hawinkels LJAC, van der Burg SH. Targeting of the cancer-associated fibroblast-T-cell axis in solid malignancies. J Clin Med. 2019;8(11):1989.

[95] Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463-479.e10.

[96] Kerdidani D, Aerakis E, Verrou K, et al. Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts. bioRxiv. 2020.

[97] Kerdidani D, Aerakis E, Verrou KM, et al. Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts. J Exp Med. 2022;219(2):e20210815.

[98] Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3(7):793-807.

[99] Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579-596.

[100] Su S, Chen J, Yao H, et al. CD10⁺GPR77⁺ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841-856.e16.

[101] Kinchen J, Chen HH, Parikh K, et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell. 2018;175(2):372-386.e17.

[102] Smillie CS, Biton M, Ordovas-Montanes J, et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178(3):714-730.e22

[103] Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26(1):44-48.

[104] Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792-804.

[105] Geng X, Chen H, Zhao L, et al. Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell Dev Biol. 2021;9:655152.

[106] Huang H, Wang Z, Zhang Y, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656-673.e7.

[107] Hutton C, Heider F, Blanco-Gomez A, et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021;39(9):1227-1244.e20.

[108] Limmer A, Ohl J, Kurts C, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8⁺ T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6(12):1348-1354.

[109] Diehl L, Schurich A, Grochtmann R, Hegenbarth S, Chen L, Knolle PA. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8⁺ T cell tolerance. Hepatology. 2008;47(1):296-305.

[110] Schurich A, Berg M, Stabenow D, et al. Dynamic regulation of CD8 T cell tolerance induction by liver sinusoidal endothelial cells. J Immunol. 2010;184(8):4107-4114.

[111] Knolle PA, Böttcher J, Huang LR. The role of hepatic immune regulation in systemic immunity to viral infection. Med Microbiol Immunol. 2015;204(1):21-27.

[112] Böttcher JP, Schanz O, Wohlleber D, et al. Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep. 2013;3(3):779-795.

[113] Höchst B, Schildberg FA, Böttcher J, et al. Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. Hepatology. 2012;56(5):1924-1933.

[114] Manes TD, Pober JS. Antigen presentation by human microvascular endothelial cells triggers ICAM-1-dependent transendothelial protrusion by, and fractalkine-dependent transendothelial migration of, effector memory CD4⁺ T cells. J Immunol. 2008;180(12):8386-8392.

[115] Marelli-Berg FM, Frasca L, Weng L, Lombardi G, Lechler RI. Antigen recognition influences transendothelial migration of CD4⁺ T cells. J Immunol. 1999;162(2):696-703.

[116] Tewalt EF, Cohen JN, Rouhani SJ, Engelhard VH. Lymphatic endothelial cells—key players in regulation of tolerance and immunity. Front Immunol. 2012;3:305.

[117] Cohen JN, Guidi CJ, Tewalt EF, et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med. 2010;207(4):681-688.

[118] Hirosue S, Vokali E, Raghavan VR, et al. Steady-state antigen scavenging, cross-presentation, and CD8⁺ T cell priming: a new role for lymphatic endothelial cells. J Immunol. 2014;192(11):5002-5011.

[119] Li CY, Park HJ, Shin J, Baik JE, Mehrara BJ, Kataru RP. Tumor-associated lymphatics upregulate MHC-II to suppress tumor-infiltrating lymphocytes. Int J Mol Sci. 2022;23(21):13470.

[120] Vokali E, Yu SS, Hirosue S, et al. Lymphatic endothelial cells prime naïve CD8⁺ T cells into memory cells under steady-state conditions. Nat Commun. 2020;11(1):538.

[121] Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393-1405.

[122] Maruhashi T, Sugiura D, Okazaki I, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022;55(5):912-924.e8.

[123] Lecocq Q, Keyaerts M, Devoogdt N, Breckpot K. The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time’s a charm. Int J Mol Sci. 2020;22(1):75.

[124] Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.

[125] Chocarro L, Blanco E, Zuazo M, et al. Understanding LAG-3 signaling. Int J Mol Sci. 2021;22(10):5282.

[126] Workman CJ, Vignali DAA. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur J Immunol. 2003;33(4):970-979.

[127] Buisson S, Triebel F. LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology. 2005;114(3):369-374.

[128] Lipson EJ, Tawbi HAH, Schadendorf D, et al. Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047). J Clin Oncol. 2021;39(15 suppl):9503.

[129] Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24-34.

[130] Maruhashi T, Sugiura D, Okazaki I, Okazaki T. LAG-3: from molecular functions to clinical applications. J ImmunoTher Cancer. 2020;8:e001014.

[131] Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. 2019;35(5):150923.

[132] Kote S, Pirog A, Bedran G, Alfaro J, Dapic I. Mass spectrometry-based identification of MHC-associated peptides. Cancers. 2020;12(3):535.

[133] Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science. 1992;255(5049):1261-1263.

[134] Yewdell JW. MHC class I immunopeptidome: past, present, and future. Mol Cell Proteomics. 2022;21(7):100230.

[135] Nielsen M, Ternette N, Barra C. The interdependence of machine learning and LC-MS approaches for an unbiased understanding of the cellular immunopeptidome. Expert Rev Proteomics. 2022;19(2):77-88.

[136] Leko V, Rosenberg SA. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell. 2020;38(4):454-472.

[137] Katayama H, Kobayashi M, Irajizad E, et al. Protein citrullination as a source of cancer neoantigens. J Immunother Cancer. 2021;9(6):e002549.

[138] Sidney J, Vela JL, Friedrich D, et al. Low HLA binding of diabetes-associated CD8⁺ T-cell epitopes is increased by post translational modifications. BMC Immunol. 2018;19(1):12.

[139] Petersen J, Purcell AW, Rossjohn J. Post-translationally modified T cell epitopes: immune recognition and immunotherapy. J Mol Med. 2009;87(11):1045-1051.

[140] Kacen A, Javitt A, Kramer MP, et al. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat Biotechnol. 2022;41:239-251.

[141] Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell. 2022;185(15):2770-2788.

[142] León-Letelier RA, Katayama H, Hanash S. Mining the immunopeptidome for antigenic peptides in cancer. Cancers. 2022;14(20):4968.

[143] Yuzhalin AE. Citrullination in cancer. Cancer Res. 2019;79(7):1274-1284.

[144] Turunen S, Koivula MK, Risteli L, Risteli J. Ureido group-specific antibodies are induced in rabbits immunized with citrulline-or homocitrulline-containing antigens. Autoimmunity. 2016;49(7):459-465.

[145] Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med. 2011;208(13):2625-2632.

[146] Ravanan P, Srikumar IF, Talwar P. Autophagy: the spotlight for cellular stress responses. Life Sci. 2017;188:53-67.

[147] Sase T, Arito M, Onodera H, et al. Hypoxia-induced production of peptidylarginine deiminases and citrullinated proteins in malignant glioma cells. Biochem Biophys Res Commun. 2017;482(1):50-56.

[148] Symonds P, Marcu A, Cook KW, Metheringham RL, Durrant LG, Brentville VA. Citrullinated epitopes identified on tumour MHC class II by peptide elution stimulate both regulatory and TH1 responses and require careful selection for optimal anti-tumour responses. Front Immunol. 2021;12:764462.

[149] Feola S, Chiaro J, Martins B, et al. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. eLife. 2022;11:e71156.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.